Takeda Enlists Real World Evidence To Boost Marketed Entyvio

09 May 2017

• By John Davis

Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.

Intestine — The Site of Intestinal Inflammation. Source: Shutterstock

Real-world evidence collected in the US has confirmed the efficacy of Takeda Pharmaceutical Co. Ltd.’s best-selling product, Entyvio (vedolizumab), in the treatment of ulcerative colitis and Crohn’s disease, as the Japanese company embraces such evidence as part of its turnaround of its pharmaceutical business.

Takeda has been reconfiguring its business over the past several years partly as a result of a former best-selling product,...